HIKAL Hikal Q3 FY25 results (Oct–Dec 2024) and concall
Hikal reported a strong Q3 FY25 with revenue of INR448 crores and EBITDA growth of 11% year-on-year, driven by improved product mix and operating leverage. The Pharma business showed significant EBIT growth, while the Crop Protection sector is beginning to stabilize. The company is focusing on NCEs and CDMO opportunities across its segments, with a healthy pipeline and strategic initiatives like Project Pinnacle expected to drive future growth and margin expansion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 453 | 448 |
| EBITDA | 75 | 72 |
| Net profit | 18 | 17 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
